Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Postmenopausal Women With Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT02340221
What this trial is testing

Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 631
Testing effectiveness (Phase 2)Study completedNCT00626106
What this trial is testing

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast TumorsMetastatic Cancer
NantCell, Inc. 156
Early research (Phase 1)Study completedNCT00328120
What this trial is testing

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

Who this might be right for
Advanced Breast Cancer
AstraZeneca 20
Large-scale testing (Phase 3)Study completedNCT01740427
What this trial is testing

Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Who this might be right for
Breast Neoplasms
Pfizer 666
Post-approval studies (Phase 4)Study completedNCT00237133
What this trial is testing

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

Who this might be right for
Locally Advanced Breast Cancer
Novartis Pharmaceuticals 112
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)UnknownNCT00927511
What this trial is testing

A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 104
Testing effectiveness (Phase 2)Ended earlyNCT03284957
What this trial is testing

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 136
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Large-scale testing (Phase 3)Study completedNCT00241449
What this trial is testing

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast CancerMetastasis
AstraZeneca 51
Not applicableNo Longer AvailableNCT05108740
What this trial is testing

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Who this might be right for
Advanced Hormone Receptor Positive (HR+) Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT00003536
What this trial is testing

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Who this might be right for
Stage IV Breast CancerRecurrent Breast Cancer
Burzynski Research Institute
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Large-scale testing (Phase 3)Study completedNCT00545077
What this trial is testing

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 380
Testing effectiveness (Phase 2)UnknownNCT03560856
What this trial is testing

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

Who this might be right for
Breast CancerHR+/HER2-negative Breast CancerMetastasis
Assistance Publique - Hôpitaux de Paris 54
Testing effectiveness (Phase 2)Study completedNCT00313170
What this trial is testing

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
AstraZeneca 144
Testing effectiveness (Phase 2)Study completedNCT02860000
What this trial is testing

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Who this might be right for
Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more
Mayo Clinic 96
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Next Page